Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment
Launched by PROFIL INSTITUT FÜR STOFFWECHSELFORSCHUNG GMBH · Jul 16, 2013
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have Type 2 diabetes mellitus based on the disease diagnostic criteria (WHO) classification
- Exclusion Criteria:
- • Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis.
About Profil Institut Für Stoffwechselforschung Gmbh
Profil Institut für Stoffwechselforschung GmbH is a leading clinical research organization specializing in metabolic disorders, with a strong focus on diabetes and obesity. With a commitment to advancing scientific knowledge and improving patient outcomes, Profil conducts innovative clinical trials that evaluate the efficacy and safety of new therapies and interventions. The organization is renowned for its expertise in metabolic research, employing cutting-edge methodologies and state-of-the-art facilities to deliver high-quality data to its partners in the pharmaceutical and biotechnology industries. Through collaboration and a patient-centered approach, Profil aims to contribute significantly to the development of effective treatments and enhance the understanding of metabolic health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Neuss, Nrw, Germany
Patients applied
Trial Officials
Christoph Kapitza, MD
Principal Investigator
Profil Institut für Stoffwechselforschung GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials